cytosine has been researched along with Cytomegalovirus Infections in 145 studies
Cytomegalovirus Infections: Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have recently shown that the artemisinin derivative artemisone, which was screened against malaria in human clinical studies, is a potent inhibitor of human cytomegalovirus (HCMV)." | 7.91 | Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus. ( Bar-On, S; Haynes, RK; Lantsberg, D; Laskov, I; Oiknine-Djian, E; Panet, A; Wolf, DG, 2019) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 7.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Human cytomegalovirus (CMV) UL54 DNA polymerase (pol) mutants with known patterns of resistance to current antivirals ganciclovir (GCV), foscarnet (FOS), and cidofovir (CDV) were tested for cyclopropavir (CPV) susceptibility by a standardized reporter-based yield reduction assay." | 7.78 | Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. ( Bowlin, TL; Chou, S; Marousek, G, 2012) |
| "Five AIDS patients with cytomegalovirus (CMV) retinitis who had received ganciclovir (GCV) therapy were followed with serial blood sampling to detectchanges both in CMV load and in the genetic composition of genes UL97 and UL54 whilst receiving cidofovir (CDV) therapy." | 7.70 | Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. ( Bowen, EF; Cherrington, JM; Emery, VC; Griffiths, PD; Johnson, MA; Lamy, PD, 1999) |
| "Both ganciclovir-sensitive and -resistant human cytomegaloviruses (HCMV) were isolated from a patient with aplastic anemia complicated with CMV retinitis and encephalitis." | 7.69 | Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir. ( Eizuru, Y; Harada, K; Ihara, S; Isashiki, Y; Minamishima, Y, 1997) |
| "Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), were evaluated for their effects on rat cytomegalovirus (RCMV)-induced interstitial pneumonitis after allogeneic bone marrow transplantation (BMTx)." | 7.68 | Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine. ( Bruggeman, CA; de Clercq, E; Havenith, M; Stals, FS; Zeytinoglu, A, 1993) |
| "Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine [DHPG], were evaluated for their inhibitory effects on human cytomegalovirus (HCMV) replication in human embryonal fibroblasts and on rat cytomegalovirus (RCMV) replication in rat embryonal fibroblasts." | 7.68 | Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo. ( Bruggeman, CA; de Clercq, E; Stals, FS, 1991) |
| "(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC, and two HPMPC-related nucleoside analogs, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, HPMPA, and (2-phosphonylmethoxyethyl)guanine, PMEG, were evaluated for their antiviral activities against guinea pig cytomegalovirus (GPCMV) infection in guinea pig embryo (GPE) cells and human cytomegalovirus (HCMV) infection in human diploid fibroblast (MRC-5) cells." | 7.68 | Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. ( Feng, JS; Fong, CK; Hsiung, GD; Li, SB; Lucia, HL; Yang, ZH, 1990) |
| "Leflunomide was selected as a last resort to avoid the nephrotoxicity of cidofovir." | 5.34 | Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. ( Abdelhalim, A; Almyroudis, NG; Battiwalla, M; Becker, J; Elefante, A; McCarthy, A; McCarthy, PL; Paplham, P; Segal, BH; Smith, P, 2007) |
| " Only the virus recovered from the brains of mice treated with HPMPC at a dosage of 50 mg/kg/week had a slightly decreased susceptibility to HPMPC." | 5.29 | Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. ( De Clercq, E; Neyts, J; Snoeck, R; Sobis, H; Vandeputte, M, 1993) |
| "5 mg/kg with concomitant oral probenecid, saline prehydration, extended dosing intervals, and drug interruption for proteinuria (19 patients)." | 5.08 | (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. ( Cundy, K; Drew, WL; Fisher, PE; Flaherty, J; Glutzer, E; Hannigan, J; James, C; Lalezari, JP; Martin, JC; Miner, D, 1995) |
| "Ganciclovir (GCV), the therapy of choice for human cytomegalovirus (CMV) infections and foscarnet, a drug used to treat GCV-resistant CMV infections was approved more than twenty years ago." | 4.87 | The search for new therapies for human cytomegalovirus infections. ( Kern, ER; Prichard, MN, 2011) |
| "We have recently shown that the artemisinin derivative artemisone, which was screened against malaria in human clinical studies, is a potent inhibitor of human cytomegalovirus (HCMV)." | 3.91 | Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus. ( Bar-On, S; Haynes, RK; Lantsberg, D; Laskov, I; Oiknine-Djian, E; Panet, A; Wolf, DG, 2019) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 3.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Eight in vitro selection experiments under brincidofovir pressure elicited the known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L and the novel exonuclease domain substitutions D413Y, E303D, and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir or 17-fold when E303G was combined with V812L." | 3.83 | Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. ( Chou, S; Ercolani, RJ; Lanier, ER, 2016) |
| "Human cytomegalovirus (CMV) UL54 DNA polymerase (pol) mutants with known patterns of resistance to current antivirals ganciclovir (GCV), foscarnet (FOS), and cidofovir (CDV) were tested for cyclopropavir (CPV) susceptibility by a standardized reporter-based yield reduction assay." | 3.78 | Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. ( Bowlin, TL; Chou, S; Marousek, G, 2012) |
| " Under immunosuppressive treatment with azathioprine and steroids, the patient developed cytomegalovirus (CMV) enteritis which was triggered by therapy-induced leukopenia." | 3.75 | [A 55-year-old woman with thymoma and hypogammaglobulinemia (Good syndrome), ulcerative colitis, and cytomegalovirus infection]. ( Baba, HA; Gerken, G; Kahraman, A; Maldonado-Lopez, E; Miller, M; Treichel, U, 2009) |
| "A human cytomegalovirus (CMV) UL54 pol exonuclease domain II mutation, D413A, found in a clinical specimen, conferred ganciclovir (GCV) and cidofovir resistance but not foscarnet resistance when incorporated into laboratory strain T2294." | 3.74 | Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. ( Chou, S; Marousek, GI, 2008) |
| "Diverse mutations in the cytomegalovirus (CMV) DNA polymerase (pol) gene confer resistance to one or more of the antiviral drugs ganciclovir, foscarnet or cidofovir." | 3.74 | Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. ( Chou, S; Li, S; Marousek, G; Weinberg, A, 2008) |
| "Emergence of human cytomegalovirus (HCMV) resistance to ganciclovir in solid-organ transplant recipients has been found to be mostly associated with primary HCMV infection." | 3.72 | Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response. ( Baldanti, F; Campanini, G; Comolli, G; Gerna, G; Lilleri, D; Ridolfo, AL; Rusconi, S, 2004) |
| "Five AIDS patients with cytomegalovirus (CMV) retinitis who had received ganciclovir (GCV) therapy were followed with serial blood sampling to detectchanges both in CMV load and in the genetic composition of genes UL97 and UL54 whilst receiving cidofovir (CDV) therapy." | 3.70 | Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. ( Bowen, EF; Cherrington, JM; Emery, VC; Griffiths, PD; Johnson, MA; Lamy, PD, 1999) |
| "Drug-resistant human cytomegalovirus (HCMV) strains were selected in human embryonic lung (HEL) fibroblasts under pressure of the (S)-3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives of cytosine (HPMPC) and adenine (HPMPA), the 2-phosphonylmethoxyethyl (PME) derivative of 2,6-diaminopurine (PMEDAP), ganciclovir (GCV), acyclovir (ACV), and foscarnet (PFA)." | 3.69 | Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. ( Andrei, G; De Clercq, E; Snoeck, R, 1996) |
| "To evaluate the decrease in intraocular pressure associated with cidofovir (1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate; HPMPC) intravitreal injections." | 3.69 | Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. ( Arevalo, JF; Banker, AS; Berry, C; De Clercq, E; Freeman, WR; Ishimoto, B; Munguia, D; Ochabski, R; Rahhal, FM; Taskintuna, I, 1997) |
| "In a human immunodeficiency virus-infected subject, cytomegalovirus (CMV) isolated 9 months after the patient began oral ganciclovir prophylaxis was resistant to ganciclovir and cidofovir and contained mutations in both UL97 and Pol coding regions." | 3.69 | Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. ( Chou, S; Drew, WL; Follansbee, SE; Guentzel, S; Lalezari, JP; Marousek, G; Miner, RC; Poscher, ME, 1997) |
| "Both ganciclovir-sensitive and -resistant human cytomegaloviruses (HCMV) were isolated from a patient with aplastic anemia complicated with CMV retinitis and encephalitis." | 3.69 | Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir. ( Eizuru, Y; Harada, K; Ihara, S; Isashiki, Y; Minamishima, Y, 1997) |
| "Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), were evaluated for their effects on rat cytomegalovirus (RCMV)-induced interstitial pneumonitis after allogeneic bone marrow transplantation (BMTx)." | 3.68 | Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine. ( Bruggeman, CA; de Clercq, E; Havenith, M; Stals, FS; Zeytinoglu, A, 1993) |
| "Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine [DHPG], were evaluated for their inhibitory effects on human cytomegalovirus (HCMV) replication in human embryonal fibroblasts and on rat cytomegalovirus (RCMV) replication in rat embryonal fibroblasts." | 3.68 | Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo. ( Bruggeman, CA; de Clercq, E; Stals, FS, 1991) |
| "(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC, and two HPMPC-related nucleoside analogs, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, HPMPA, and (2-phosphonylmethoxyethyl)guanine, PMEG, were evaluated for their antiviral activities against guinea pig cytomegalovirus (GPCMV) infection in guinea pig embryo (GPE) cells and human cytomegalovirus (HCMV) infection in human diploid fibroblast (MRC-5) cells." | 3.68 | Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. ( Feng, JS; Fong, CK; Hsiung, GD; Li, SB; Lucia, HL; Yang, ZH, 1990) |
| " Subsequent dosing and frequency were determined by clinical response and side effects, as assessed by the treating physician." | 2.80 | Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients. ( Braverman, RS; Caruso Brown, AE; Cohen, MN; Giller, R; Levin, MJ; Rooney, JF; Tong, S, 2015) |
| "Diarrhea was dose-limiting in this population at a dose of 200 mg twice weekly." | 2.78 | CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. ( Boeckh, M; Brundage, TM; Godkin, S; Marty, FM; Momméja-Marin, H; Mullane, KM; Papanicolaou, GA; Robertson, AT; Rowley, SD; Vance, E; Winston, DJ, 2013) |
| " New antiviral agents are urgently needed with less adverse effects, good oral bioavailability and possibly novel targets or mechanisms of action to avoid cross-resistance and to improve the ability to suppress the selection of resistant virus strains by combination therapy." | 2.45 | Antiviral treatment of cytomegalovirus infection and resistant strains. ( Bunjes, D; Härter, G; Mertens, T; Michel, D; Schreiber, A; Schubert, A, 2009) |
| " The emergence of drug resistance may be reduced by optimization of host immunity, use of potent antiviral drug regimens, and adherence to dosing regimens that adequately suppress viral replication." | 2.41 | Cytomegalovirus drug resistance and clinical implications. ( Chou, SW, 2001) |
| " Since cidofovir is cleared almost entirely by the kidneys, dosage adjustments must be made in patients with impaired renal function." | 2.40 | Cidofovir in the treatment of cytomegaloviral disease. ( Fan-Havard, P; Kendle, JB, 1998) |
| "Agents available to treat herpesvirus infections include idoxuridine, trifluridine, vidarabine and acyclovir for the topical treatment of herpetic eye infections; vidarabine and acyclovir for the systemic (intravenous) treatment of herpes encephalitis; acyclovir for the topical and systemic (oral) treatment of genital herpes; acyclovir for the systemic (intravenous, oral) treatment of HSV or varicella-zoster (VZV) infections in immunosuppressed patients; brivudin for the systemic (oral) treatment of HSV-1 or VZV infections in immunosuppressed patients; and ganciclovir and foscarnet for the systemic (intravenous) treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 2.38 | Antivirals for the treatment of herpesvirus infections. ( De Clercq, E, 1993) |
| "We reviewed data of 4 cancer patients with resistant CMV or herpes simplex virus (HSV) infections and were treated with brincidofovir under emergency IND application." | 1.43 | Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. ( Ariza-Heredia, EJ; Chemaly, RF; El Chaer, F; El-Haddad, D; Gulbis, AM; Mulanovich, VE; Shah, DP; Shpall, EJ; Vanichanan, J, 2016) |
| " To date, a safe and effective therapy for CMV-induced hearing loss does not exist." | 1.40 | Safety of cidofovir by intratympanic delivery technique. ( Choo, DI; Nassar, M; Reece, AL; Sidell, DR; Ward, JA, 2014) |
| "A severely T-cell-depleted patient with chronic lymphocytic leukemia developed CMV pneumonia and high plasma viral loads that were poorly responsive to antiviral therapy." | 1.40 | Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. ( Chou, S; Ercolani, RJ; Lefterova, MI; Pinsky, BA; Sahoo, MK; Strasfeld, LM, 2014) |
| " We evaluated the in vivo efficacy of an orally bioavailable analog of cidofovir, hexadecyloxypropyl-cidofovir (HDP-CDV), against guinea pig CMV (GPCMV) in a guinea pig model of congenital CMV infection." | 1.37 | Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection. ( Beadle, JR; Bernstein, DI; Bravo, FJ; Cardin, RD; Hostetler, KY, 2011) |
| "Hemorrhagic cystitis is a common complication in hematopoietic stem cell transplant recipients." | 1.35 | Hyperbaric oxygen therapy in BKV-associated hemorrhagic cystitis refractory to intravenous and intravesical cidofovir: case report and review of literature. ( Benedetti, E; Ceccherini-Nelli, L; Focosi, D; Galimberti, S; Maggi, F; Papineschi, F; Petrini, M; Pistolesi, D, 2009) |
| "Leflunomide was selected as a last resort to avoid the nephrotoxicity of cidofovir." | 1.34 | Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. ( Abdelhalim, A; Almyroudis, NG; Battiwalla, M; Becker, J; Elefante, A; McCarthy, A; McCarthy, PL; Paplham, P; Segal, BH; Smith, P, 2007) |
| "To improve the oral bioavailability of cidofovir (CDV), a series of ether lipid ester prodrugs were synthesized and evaluated for activity against murine cytomegalovirus (MCMV) infection." | 1.32 | Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. ( Beadle, JR; Collins, DJ; Hostetler, KY; Kern, ER; Quenelle, DC; Wan, WB, 2004) |
| "An exacerbation of the myelitis, retinitis, encephalitis and colitis was observed and a cytomegalovirus infection diagnosed." | 1.31 | CMV complications in common variable immunodeficiency. ( Schmidt, RE; Werwitzke, S; Witte, T, 2000) |
| " Further, blood chemistry analysis showed no adverse effects of CHPMPC treatment on kidney or liver function." | 1.31 | Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals. ( Bernstein, DI; Bourne, N; Bravo, FJ, 2000) |
| " The dosage of CDV was 1 to 5 mg/kg per week followed by maintenance every other week in some patients." | 1.31 | Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. ( Bacigalupo, A; Bornhäuser, M; Cesaro, S; Cordonnier, C; Crooks, B; Dekker, A; Deliliers, GL; Einsele, H; Gratecos, N; Klingebiel, T; Ljungman, P; Matthes-Martin, S; Musso, M; Platzbecker, U; Ribaud, P; Tagliaferri, E; Trenschel, R; Ullmann, AJ; Ullmann, J; Wacker, P, 2001) |
| " In case of response with a decreasing number of pp65-positive leukocytes, CDV was scheduled in a dosage of 5 mg/kg body weight once a week for 2 weeks followed by maintenance therapy every 2 weeks in an outpatient setting." | 1.31 | Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. ( Bandt, D; Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Geissler, G; Helwig, A; Platzbecker, U; Plettig, R; Rethwilm, A; Schuler, U; Thiede, C, 2001) |
| " Treatment with one dosage of HPMPC at 20 mg/kg effectively reduced virus titers." | 1.30 | Effective treatment of experimental cytomegalovirus-induced encephalo-meningitis in immunocompromised rats with HPMPC. ( Bruggeman, CA; Kloover, JS; Stals, FS; Vanagt, WY, 1997) |
| "The initial and maintenance treatment of CMV retinitis must be individualized based on the characteristics of the lesions, including location and extent, specific patient factors, and characteristics of available therapies among others." | 1.30 | Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. ( Benson, CA; Deutsch, TA; Dieterich, DT; Drew, WL; Feinberg, J; Friedberg, DN; Griffiths, PD; Hardy, WD; Holland, GN; Jabs, DA; Jacobson, MA; Kessler, HA; Polis, MA; Powderly, WG; Spector, SA; Walmsley, S; Whitley, RJ, 1998) |
| "This iritis was characterized by infiltration of acute inflammatory cells mixed with cytomegalic cells, which was confirmed by CMV-specific immunohistochemical staining." | 1.30 | Cytomegalovirus iritis. ( Avila, CP; Cheng, L; Freeman, WR; Keefe, KS; Macdonald, JC; Rao, NA, 1998) |
| " Efficacy trials with CMV disease will define the therapeutic utility and optimal dosing interval for cidofovir." | 1.29 | Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. ( Baird, BF; Davey, RT; Falloon, J; Fisher, PE; Jaffe, HS; Kovacs, JA; Manischewitz, JF; Polis, MA; Spooner, KM; Walker, RE, 1995) |
| " Only the virus recovered from the brains of mice treated with HPMPC at a dosage of 50 mg/kg/week had a slightly decreased susceptibility to HPMPC." | 1.29 | Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. ( De Clercq, E; Neyts, J; Snoeck, R; Sobis, H; Vandeputte, M, 1993) |
| "0 mg/kg of body weight and declined biexponentially with an overall mean +/- standard deviation terminal half-life of 2." | 1.29 | Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. ( Cundy, KC; Fisher, PE; Flaherty, J; Hitchcock, MJ; Jaffe, HS; Lalezari, JP; Lietman, PS; Petty, BG; Polis, MA; Wachsman, M, 1995) |
| "Some advances in AIDS research have been limited by this lack of urgency in implementation, optimization, or equitable delivery to the broad patient community." | 1.29 | Advances, challenges and growing frustration. ( , 1995) |
| "These results indicate that MAIDS can be used as a model for evaluating antivirals in an immunocompromised host, and suggest that both PMEA and HPMPC may be useful in the treatment of opportunistic CMV and HSV-1 infections." | 1.28 | Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. ( De Castro, LM; De Clercq, E; Gangemi, JD; Ghaffar, A; Kern, ER; Mayer, EP; Vogt, PE, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.69) | 18.7374 |
| 1990's | 56 (38.62) | 18.2507 |
| 2000's | 57 (39.31) | 29.6817 |
| 2010's | 30 (20.69) | 24.3611 |
| 2020's | 1 (0.69) | 2.80 |
| Authors | Studies |
|---|---|
| Lipka, E | 2 |
| Chadderdon, AM | 2 |
| Harteg, CC | 2 |
| Doherty, MK | 2 |
| Simon, ES | 2 |
| Domagala, JM | 2 |
| Reyna, DM | 2 |
| Hutchings, KM | 2 |
| Gan, X | 2 |
| White, AD | 2 |
| Hartline, CB | 6 |
| Harden, EA | 2 |
| Keith, KA | 3 |
| Prichard, MN | 5 |
| James, SH | 3 |
| Cardin, RD | 5 |
| Bernstein, DI | 7 |
| Spencer, JF | 2 |
| Tollefson, AE | 2 |
| Wold, WSM | 2 |
| Toth, K | 2 |
| Oiknine-Djian, E | 1 |
| Bar-On, S | 1 |
| Laskov, I | 1 |
| Lantsberg, D | 1 |
| Haynes, RK | 1 |
| Panet, A | 1 |
| Wolf, DG | 1 |
| Bruminhent, J | 1 |
| Rotjanapan, P | 1 |
| Watcharananan, SP | 1 |
| Echenique, IA | 1 |
| Beltran, D | 1 |
| Ramirez-Ruiz, L | 1 |
| Najafian, N | 1 |
| Agrawal, N | 1 |
| Frange, P | 1 |
| Leruez-Ville, M | 1 |
| O'Brien, MS | 1 |
| Markovich, KC | 1 |
| Selleseth, D | 1 |
| DeVita, AV | 1 |
| Sethna, P | 1 |
| Gentry, BG | 1 |
| Marty, FM | 2 |
| Winston, DJ | 2 |
| Chemaly, RF | 2 |
| Mullane, KM | 2 |
| Shore, TB | 1 |
| Papanicolaou, GA | 3 |
| Chittick, G | 2 |
| Brundage, TM | 2 |
| Wilson, C | 2 |
| Morrison, ME | 1 |
| Foster, SA | 1 |
| Nichols, WG | 2 |
| Boeckh, MJ | 1 |
| Price, NB | 1 |
| Lanier, ER | 3 |
| Rowley, SD | 1 |
| Vance, E | 1 |
| Robertson, AT | 1 |
| Godkin, S | 1 |
| Momméja-Marin, H | 3 |
| Boeckh, M | 3 |
| Fischer, L | 3 |
| Laib Sampaio, K | 1 |
| Jahn, G | 3 |
| Hamprecht, K | 3 |
| Göhring, K | 3 |
| Ward, JA | 1 |
| Sidell, DR | 1 |
| Nassar, M | 1 |
| Reece, AL | 1 |
| Choo, DI | 2 |
| Gregg, K | 1 |
| Hakki, M | 1 |
| Kaul, DR | 1 |
| Sellar, RS | 1 |
| Peggs, KS | 2 |
| Chou, S | 9 |
| Ercolani, RJ | 2 |
| Sahoo, MK | 1 |
| Lefterova, MI | 1 |
| Strasfeld, LM | 1 |
| Pinsky, BA | 1 |
| Griffiths, P | 1 |
| Lumley, S | 1 |
| Murphy, WJ | 1 |
| Lee, YJ | 1 |
| Young, JW | 1 |
| Seshan, SV | 1 |
| Boruchov, AM | 1 |
| Glezerman, IG | 1 |
| Caruso Brown, AE | 1 |
| Cohen, MN | 1 |
| Tong, S | 1 |
| Braverman, RS | 1 |
| Rooney, JF | 1 |
| Giller, R | 1 |
| Levin, MJ | 1 |
| Mareri, A | 1 |
| Lasorella, S | 1 |
| Iapadre, G | 1 |
| Maresca, M | 1 |
| Tambucci, R | 1 |
| Nigro, G | 1 |
| Sampaio, KL | 2 |
| Foster, S | 1 |
| Brundage, T | 1 |
| Kleiboeker, S | 1 |
| Colville, D | 1 |
| Imrich, E | 1 |
| Hofmann, J | 1 |
| Lilleri, D | 2 |
| Gerna, G | 3 |
| El-Haddad, D | 1 |
| El Chaer, F | 1 |
| Vanichanan, J | 1 |
| Shah, DP | 1 |
| Ariza-Heredia, EJ | 1 |
| Mulanovich, VE | 1 |
| Gulbis, AM | 1 |
| Shpall, EJ | 1 |
| Faure, E | 1 |
| Galperine, T | 1 |
| Cannesson, O | 1 |
| Alain, S | 2 |
| Gnemmi, V | 1 |
| Goeminne, C | 1 |
| Dewilde, A | 1 |
| Béné, J | 1 |
| Lasri, M | 1 |
| Lessore de Sainte Foy, C | 1 |
| Lionet, A | 1 |
| Torres-Madriz, G | 1 |
| Boucher, HW | 1 |
| Focosi, D | 1 |
| Maggi, F | 1 |
| Pistolesi, D | 1 |
| Benedetti, E | 1 |
| Papineschi, F | 1 |
| Galimberti, S | 1 |
| Ceccherini-Nelli, L | 1 |
| Petrini, M | 1 |
| Hubacek, P | 1 |
| Keslova, P | 1 |
| Formankova, R | 1 |
| Pochop, P | 1 |
| Cinek, O | 1 |
| Zajac, M | 1 |
| Lochmanova, J | 1 |
| Stary, J | 1 |
| Sedlacek, P | 1 |
| Péter, A | 1 |
| Telkes, G | 1 |
| Varga, M | 1 |
| Járay, J | 1 |
| Schreiber, A | 1 |
| Härter, G | 1 |
| Schubert, A | 1 |
| Bunjes, D | 1 |
| Mertens, T | 1 |
| Michel, D | 1 |
| Kahraman, A | 1 |
| Miller, M | 1 |
| Maldonado-Lopez, E | 1 |
| Baba, HA | 1 |
| Treichel, U | 1 |
| Gerken, G | 1 |
| Dvorak, CC | 1 |
| Cowan, MJ | 1 |
| Horn, B | 1 |
| Weintrub, PS | 1 |
| Lurain, NS | 1 |
| Bravo, FJ | 5 |
| Beadle, JR | 5 |
| Hostetler, KY | 5 |
| Kern, ER | 9 |
| Marousek, G | 3 |
| Bowlin, TL | 1 |
| Goldsmith, PM | 1 |
| Husain, MM | 1 |
| Carmichael, A | 1 |
| Zhang, H | 1 |
| Middleton, SJ | 1 |
| Kimberlin, DW | 1 |
| Zaia, JA | 2 |
| Leśnikowski, ZJ | 1 |
| Paradowska, E | 1 |
| Przepiórkiewicz, M | 1 |
| Olejniczak, A | 1 |
| Emery, VC | 4 |
| Snoeck, R | 4 |
| De Clercq, E | 13 |
| Papanicolaou, G | 1 |
| Rubin, R | 1 |
| Wingard, JR | 1 |
| Zaia, J | 1 |
| Bourne, N | 2 |
| Schleiss, MR | 2 |
| Baldanti, F | 2 |
| Campanini, G | 1 |
| Comolli, G | 1 |
| Ridolfo, AL | 1 |
| Rusconi, S | 1 |
| Ducancelle, A | 1 |
| Belloc, S | 1 |
| Scieux, C | 1 |
| Malphettes, M | 1 |
| Petit, F | 1 |
| Brouet, JC | 1 |
| Sanson Le Pors, MJ | 1 |
| Mazeron, MC | 1 |
| Lurain, N | 1 |
| Bidanset, DJ | 2 |
| Wan, WB | 3 |
| Meyerle, JH | 1 |
| Turiansky, GW | 1 |
| Collins, DJ | 2 |
| Quenelle, DC | 2 |
| Nagafuji, K | 1 |
| Aoki, K | 1 |
| Henzan, H | 1 |
| Kato, K | 1 |
| Miyamoto, T | 1 |
| Eto, T | 1 |
| Nagatoshi, Y | 1 |
| Ohba, T | 1 |
| Obama, K | 1 |
| Gondo, H | 1 |
| Harada, M | 1 |
| Cesaro, S | 2 |
| Zhou, X | 1 |
| Manzardo, C | 1 |
| Buonfrate, D | 1 |
| Cusinato, R | 1 |
| Tridello, G | 1 |
| Mengoli, C | 1 |
| Palù, G | 1 |
| Messina, C | 1 |
| Douthwaite, ST | 1 |
| Taegtmeyer, M | 1 |
| Stow, R | 1 |
| Mwandumba, HC | 1 |
| Hart, IJ | 1 |
| Beeching, NJ | 1 |
| Tan, HH | 1 |
| Goh, CL | 1 |
| White, DR | 1 |
| Stroup, G | 1 |
| Scott, GM | 1 |
| Weinberg, A | 2 |
| Rawlinson, WD | 1 |
| Battiwalla, M | 1 |
| Paplham, P | 1 |
| Almyroudis, NG | 1 |
| McCarthy, A | 1 |
| Abdelhalim, A | 1 |
| Elefante, A | 1 |
| Smith, P | 1 |
| Becker, J | 1 |
| McCarthy, PL | 1 |
| Segal, BH | 1 |
| Ruiz, JC | 1 |
| Aldern, KA | 1 |
| Eizuru, Y | 2 |
| Kazory, A | 1 |
| Singapuri, S | 1 |
| Wadhwa, A | 1 |
| Ejaz, AA | 1 |
| Michaels, MG | 1 |
| Marousek, GI | 1 |
| Pettway, LR | 1 |
| Li, S | 1 |
| Cundy, KC | 2 |
| Petty, BG | 1 |
| Flaherty, J | 2 |
| Fisher, PE | 3 |
| Polis, MA | 3 |
| Wachsman, M | 1 |
| Lietman, PS | 1 |
| Lalezari, JP | 6 |
| Hitchcock, MJ | 4 |
| Jaffe, HS | 4 |
| Drew, WL | 6 |
| Glutzer, E | 1 |
| James, C | 1 |
| Miner, D | 1 |
| Cundy, K | 1 |
| Hannigan, J | 1 |
| Martin, JC | 2 |
| Spooner, KM | 1 |
| Baird, BF | 1 |
| Manischewitz, JF | 1 |
| Falloon, J | 1 |
| Davey, RT | 1 |
| Kovacs, JA | 1 |
| Walker, RE | 1 |
| Neyts, J | 4 |
| Stals, FS | 5 |
| Zeytinoglu, A | 2 |
| Havennith, M | 1 |
| Bruggeman, CA | 5 |
| Havenith, M | 1 |
| Sobis, H | 1 |
| Vandeputte, M | 1 |
| Cherrington, JM | 2 |
| Miner, R | 1 |
| Xiong, X | 1 |
| Smith, JL | 1 |
| Kim, C | 1 |
| Huang, ES | 1 |
| Chen, MS | 2 |
| Jabs, DA | 3 |
| Rahhal, FM | 3 |
| Arevalo, JF | 2 |
| Chavez de la Paz, E | 1 |
| Munguia, D | 2 |
| Azen, SP | 1 |
| Freeman, WR | 5 |
| Flaherty, JF | 1 |
| Danner, SA | 1 |
| Stagg, RJ | 1 |
| Andrei, G | 1 |
| Smee, DF | 2 |
| Sidwell, RW | 2 |
| Barnett, BB | 1 |
| Cihlar, T | 1 |
| Cunningham, ET | 2 |
| Harada, K | 1 |
| Isashiki, Y | 1 |
| Ihara, S | 1 |
| Minamishima, Y | 1 |
| Davis, JL | 1 |
| Taskintuna, I | 3 |
| Weinberg, DV | 1 |
| Feuer, WJ | 1 |
| Leonard, RE | 1 |
| Friedberg, DN | 2 |
| Blick, G | 1 |
| Garton, T | 1 |
| Hopkins, U | 1 |
| LaGravinese, L | 1 |
| Kloover, JS | 1 |
| Vanagt, WY | 1 |
| Sadler, M | 1 |
| Morris-Jones, S | 1 |
| Nelson, M | 1 |
| Gazzard, BG | 1 |
| Banker, AS | 1 |
| Ishimoto, B | 1 |
| Berry, C | 1 |
| Ochabski, R | 1 |
| Guentzel, S | 1 |
| Follansbee, SE | 1 |
| Poscher, ME | 1 |
| Miner, RC | 1 |
| Pérez, JL | 1 |
| Takahashi, K | 1 |
| Capparelli, EV | 1 |
| Whitley, RJ | 1 |
| Jacobson, MA | 1 |
| Holland, GN | 1 |
| Dieterich, DT | 1 |
| Hardy, WD | 1 |
| Deutsch, TA | 1 |
| Feinberg, J | 1 |
| Spector, SA | 1 |
| Walmsley, S | 1 |
| Powderly, WG | 1 |
| Griffiths, PD | 2 |
| Benson, CA | 1 |
| Kessler, HA | 1 |
| Vogel, JU | 2 |
| Scholz, M | 2 |
| Cinatl, J | 2 |
| Cheng, L | 1 |
| Rao, NA | 1 |
| Keefe, KS | 1 |
| Avila, CP | 1 |
| Macdonald, JC | 1 |
| Kendle, JB | 1 |
| Fan-Havard, P | 1 |
| Cheung, TW | 1 |
| Teich, SA | 1 |
| Buchanan, J | 1 |
| Davis, LJ | 1 |
| Bowen, EF | 1 |
| Lamy, PD | 1 |
| Johnson, MA | 1 |
| Safrin, S | 1 |
| Cherrington, J | 1 |
| Cochereau, I | 1 |
| Doan, S | 1 |
| Diraison, MC | 1 |
| Mousalatti, H | 1 |
| Guvenisik, N | 1 |
| Ren, L | 1 |
| Hoang-Xuan, T | 1 |
| Kotchetkov, R | 1 |
| Weimer, E | 1 |
| Blaheta, RA | 1 |
| Gümbel, HO | 1 |
| Doerr, HW | 1 |
| Bolger, G | 1 |
| Lapeyre, N | 1 |
| Rhéaume, M | 1 |
| Kibler, P | 1 |
| Bousquet, C | 1 |
| Garneau, M | 1 |
| Cordingley, M | 1 |
| Einsele, H | 2 |
| Hebart, H | 1 |
| Held, TK | 1 |
| Biel, SS | 1 |
| Nitsche, A | 1 |
| Kurth, A | 1 |
| Chen, S | 1 |
| Gelderblom, HR | 1 |
| Siegert, W | 1 |
| Witte, T | 1 |
| Werwitzke, S | 1 |
| Schmidt, RE | 1 |
| Scott, RA | 1 |
| Pavesio, C | 1 |
| Ketteler, M | 1 |
| Preuschof, L | 1 |
| Mertz, A | 1 |
| Stöffler-Meilicke, M | 1 |
| Schäfer, H | 1 |
| Distler, A | 1 |
| Offermann, G | 1 |
| Ljungman, P | 1 |
| Deliliers, GL | 1 |
| Platzbecker, U | 2 |
| Matthes-Martin, S | 1 |
| Bacigalupo, A | 1 |
| Ullmann, J | 1 |
| Musso, M | 1 |
| Trenschel, R | 1 |
| Ribaud, P | 1 |
| Bornhäuser, M | 2 |
| Crooks, B | 1 |
| Dekker, A | 1 |
| Gratecos, N | 1 |
| Klingebiel, T | 1 |
| Tagliaferri, E | 1 |
| Ullmann, AJ | 1 |
| Wacker, P | 1 |
| Cordonnier, C | 1 |
| Castagnola, E | 2 |
| Cristina, E | 2 |
| Dallorso, S | 1 |
| Lanino, E | 2 |
| Giacchino, R | 1 |
| Bruning, JH | 1 |
| Persoons, M | 1 |
| Lemström, K | 1 |
| Bandt, D | 1 |
| Thiede, C | 1 |
| Helwig, A | 1 |
| Freiberg-Richter, J | 1 |
| Schuler, U | 1 |
| Plettig, R | 1 |
| Geissler, G | 1 |
| Rethwilm, A | 1 |
| Ehninger, G | 1 |
| Torres, G | 1 |
| Kiehl, MG | 1 |
| Basara, N | 1 |
| Miano, M | 1 |
| Morreale, G | 1 |
| Chierici, M | 1 |
| Bhorade, SM | 1 |
| Sandesara, C | 1 |
| Garrity, ER | 1 |
| Vigneswaran, WT | 1 |
| Norwick, L | 1 |
| Alkan, S | 1 |
| Husain, AN | 1 |
| McCabe, MA | 1 |
| Yeldandi, V | 1 |
| Rybak, RJ | 1 |
| Salmon-Ceron, D | 1 |
| Arnulf, B | 1 |
| Chebbi, F | 1 |
| Lefrere, F | 1 |
| Ait Arkoub, Z | 1 |
| Varet, B | 1 |
| Fillet, AM | 1 |
| Chakrabarti, S | 1 |
| Collingham, KE | 1 |
| Osman, H | 1 |
| Fegan, CD | 1 |
| Milligan, DW | 1 |
| Zedtwitz-Liebenstein, K | 1 |
| Presterl, E | 1 |
| Deviatko, E | 1 |
| Graninger, W | 1 |
| Chou, SW | 1 |
| Bosi, A | 1 |
| Bartolozzi, B | 1 |
| Vannucchi, AM | 1 |
| Orsi, A | 1 |
| Guidi, S | 1 |
| Rossi Ferrini, P | 1 |
| Williams, IG | 1 |
| Balzarini, J | 1 |
| Naesens, L | 1 |
| Morris, JL | 1 |
| Leonhardt, JA | 1 |
| Mead, JR | 1 |
| Holy, A | 1 |
| De Castro, LM | 1 |
| Ghaffar, A | 1 |
| Mayer, EP | 1 |
| Vogt, PE | 1 |
| Gangemi, JD | 1 |
| Schols, D | 1 |
| Himpens, B | 1 |
| Bronson, JJ | 1 |
| Ferrara, LM | 1 |
| Ho, HT | 1 |
| Woods, KL | 1 |
| Ghazzouli, I | 1 |
| Soike, KF | 1 |
| Li, SB | 1 |
| Yang, ZH | 1 |
| Feng, JS | 1 |
| Fong, CK | 1 |
| Lucia, HL | 1 |
| Hsiung, GD | 1 |
| Brideau, RJ | 1 |
| Nicholas, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients[NCT01769170] | Phase 3 | 452 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients[NCT00942305] | Phase 2 | 239 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The incidence of clinically significant cytomegalovirus (CMV) infection through Week 14.~Blood and urine for virologic evaluations were collected at screening, pre-dose on the first day of study drug administration, and at pre-specified intervals throughout the treatment phases of the study and sent to a designated central virology laboratory for analysis. Blood samples were used for real-time assay of CMV viremia in plasma using a qPCR assay. Urine samples were stored for possible future retrospective analyses of CMV." (NCT01769170)
Timeframe: 14 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Brincidofovir | 74 |
| Placebo | 57 |
"Clinically significant cytomegalovirus (CMV) infection was defined by either of the following outcomes:~Onset of CMV end-organ disease; or~Initiation of anti-CMV-specific preemptive therapy based on documented CMV viremia (as measured by the central virology laboratory) and the clinical condition of the subject.~CMV viremia (i.e., the measurement of CMV DNA in plasma) was determined by the designated central virology laboratory at all scheduled visits via quantitative polymerase chain reaction (qPCR) testing using the Roche COBAS® AmpliPrep/COBAS® TaqMan® CMV Test." (NCT01769170)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Brincidofovir | 155 |
| Placebo | 78 |
The primary efficacy endpoint was a binomial outcome of failure to prevent cytomegalovirus (CMV) infection defined as CMV DNAemia >200 copies/mL obtained at the time of the last treatment with study drug or diagnosis of CMV disease at some point during the treatment phase. (NCT00942305)
Timeframe: Randomization to Week 8 post-treatment (~19 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 BCV | 13 |
| Cohort 1 Placebo | 4 |
| Cohort 2 BCV | 6 |
| Cohort 2 Placebo | 4 |
| Cohort 3 BCV | 12 |
| Cohort 3 Placebo | 4 |
| Cohort 4 BCV | 7 |
| Cohort 4 Placebo | 3 |
| Cohort 4a BCV | 5 |
| Cohort 4a Placebo | 7 |
38 reviews available for cytosine and Cytomegalovirus Infections
| Article | Year |
|---|---|
Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections.
Topics: Acetates; Antiviral Agents; Benzimidazoles; Cytomegalovirus Infections; Cytosine; Ganciclovir; Human | 2018 |
Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.
Topics: Acetates; Antiviral Agents; Benzimidazoles; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; H | 2014 |
Cytomegalovirus.
Topics: Acetates; Antiviral Agents; Benzimidazoles; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalo | 2014 |
Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.
Topics: Acetates; Adoptive Transfer; Animals; Antiviral Agents; Benzimidazoles; Cell- and Tissue-Based Thera | 2015 |
Anti-viral therapy for congenital cytomegalovirus infection: pharmacokinetics, efficacy and side effects.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Foscarnet; Ganciclovir; Humans; I | 2016 |
Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.
Topics: Acetates; Adult; Animals; Antiviral Agents; Asymptomatic Diseases; Benzimidazoles; Clinical Trials a | 2016 |
Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Topics: Antiviral Agents; Chemoprevention; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2008 |
[Gastrointestinal cytomegalovirus infections in organ transplant patients].
Topics: Acyclovir; Antiviral Agents; Biopsy; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosin | 2008 |
Antiviral treatment of cytomegalovirus infection and resistant strains.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Resistance, Viral; Drug Ther | 2009 |
Antiviral drug resistance of human cytomegalovirus.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2010 |
The search for new therapies for human cytomegalovirus infections.
Topics: Antiviral Agents; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; F | 2011 |
Prevention and management of CMV-related problems after hematopoietic stem cell transplantation.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Fosca | 2002 |
[Drugs against human cytomegalovirus].
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infec | 2002 |
Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients.
Topics: Cidofovir; Cytomegalovirus Infections; Cytosine; DNA Virus Infections; Humans; Immunocompromised Hos | 2002 |
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.
Topics: Acyclovir; Antigens, CD34; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Foscar | 2003 |
Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Cidofovir; Cytomegaloviru | 2004 |
Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Ad | 2006 |
[Mechanism of drug-resistance in human cytomegalovirus].
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2007 |
Treatment of congenital cytomegalovirus: where are we now?
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Female; Foscarnet; Ganciclovir; H | 2007 |
Antivirals for the treatment of herpesvirus infections.
Topics: Acyclovir; Antiviral Agents; Belgium; Bromodeoxyuridine; Cidofovir; Cytomegalovirus Infections; Cyto | 1993 |
Management of cytomegalovirus disease.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Therapy, Combination; Foscar | 1995 |
A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC).
Topics: Animals; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytomegalovirus Infections; Cytosine | 1996 |
Cidofovir.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Humans; Organophosphonates; Organ | 1997 |
Resistance to antivirals in human cytomegalovirus: mechanisms and clinical significance.
Topics: Antiviral Agents; Cidofovir; Codon; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 1997 |
[Recent advances in antiviral drugs--antiviral agents to HCMV, HHV-6, and HHV-7].
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 1998 |
Treatment of cytomegalovirus diseases.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosin | 1997 |
Cidofovir in the treatment of cytomegaloviral disease.
Topics: Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytomegalovirus Infections; Cytosine; Drug In | 1998 |
Cytomegalovirus infection in patients with HIV infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1999 |
Cytomegalovirus: disease syndromes and treatment.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Central Nervous System Diseases; Chorioreti | 1999 |
Cidofovir. Review of current and potential clinical uses.
Topics: AIDS-Related Opportunistic Infections; Animals; Antiviral Agents; Cidofovir; Clinical Trials as Topi | 1999 |
Cytomegalovirus drug resistance.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Resistance; Foscarnet; Ganci | 1998 |
Uveitis in HIV positive patients.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; HIV Seropositivity; Humans; Organ | 2000 |
Cytomegalovirus infection following stem cell transplantation.
Topics: Acyclovir; Antibodies, Viral; Antiviral Agents; Blood Donors; Cidofovir; Cytomegalovirus; Cytomegalo | 1999 |
Progress in understanding cytomegalovirus drug resistance.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
Cytomegalovirus infection: the point in 2001.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiv | 2001 |
Cytomegalovirus drug resistance and clinical implications.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
Management of CMV disease in HIV infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1999 |
Value of animal models to evaluate agents with potential activity against human cytomegalovirus.
Topics: Acyclovir; Animals; Antiviral Agents; Cell Division; Cell Survival; Cells, Cultured; Cidofovir; Cyto | 1991 |
9 trials available for cytosine and Cytomegalovirus Infections
| Article | Year |
|---|---|
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Allografts; Cytomegalovirus; Cytomegalovirus Infectio | 2019 |
CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.
Topics: Administration, Oral; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Cytosine | 2013 |
Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients.
Topics: Acute Kidney Injury; Adenovirus Infections, Human; Adolescent; Antiviral Agents; BK Virus; Child; Ch | 2015 |
Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA Polymerase | 2016 |
Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients.
Topics: Adenoviridae; Adenoviridae Infections; Adolescent; Adult; Antiviral Agents; Child; Cidofovir; Cystit | 2004 |
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Creatine; Cytomegalovirus | 1995 |
Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug.
Topics: Adult; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, Microbial; | 1996 |
Opportunistic infection highlights from the 35th ICAAC.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Bacterial Vaccines; CD4 Lymphocy | 1995 |
Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
98 other studies available for cytosine and Cytomegalovirus Infections
| Article | Year |
|---|---|
NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety Margin.
Topics: Animals; Antiviral Agents; Biological Availability; Cidofovir; Cytomegalovirus Infections; Cytosine; | 2023 |
NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety Margin.
Topics: Animals; Antiviral Agents; Biological Availability; Cidofovir; Cytomegalovirus Infections; Cytosine; | 2023 |
NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety Margin.
Topics: Animals; Antiviral Agents; Biological Availability; Cidofovir; Cytomegalovirus Infections; Cytosine; | 2023 |
NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety Margin.
Topics: Animals; Antiviral Agents; Biological Availability; Cidofovir; Cytomegalovirus Infections; Cytosine; | 2023 |
Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus.
Topics: Acetates; Antiviral Agents; Artemisinins; Benzimidazoles; Cidofovir; Cytomegalovirus; Cytomegaloviru | 2019 |
Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2017 |
Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report.
Topics: Aged; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Dose-Respo | 2017 |
In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
Topics: Antiviral Agents; Benzimidazoles; Cell Line; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovi | 2018 |
Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Cells, Cultured; Chromosomes, Artificial, Bact | 2013 |
Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
Topics: Antiviral Agents; Chromosomes, Artificial, Bacterial; Cidofovir; Cytomegalovirus; Cytomegalovirus In | 2013 |
Safety of cidofovir by intratympanic delivery technique.
Topics: Animals; Antiviral Agents; Cidofovir; Cochlea; Cytomegalovirus Infections; Cytosine; Disease Models, | 2014 |
UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2014 |
Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2014 |
Brincidofovir for polyomavirus-associated nephropathy after allogeneic hematopoietic stem cell transplantation.
Topics: BK Virus; Cytomegalovirus Infections; Cytosine; Hematopoietic Stem Cell Transplantation; Humans; Imm | 2015 |
Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay.
Topics: Adult; Antiviral Agents; Cell Line; Child; Chromosomes, Artificial, Bacterial; Cidofovir; Cytomegalo | 2015 |
Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2016 |
Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Topics: Adolescent; Adult; Antiviral Agents; Child; Chromosomes, Artificial, Bacterial; Cidofovir; Cytomegal | 2016 |
Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.
Topics: Aged; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus; Cytomegalovirus Infections; Cytos | 2016 |
Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection.
Topics: Acute Kidney Injury; Antiviral Agents; Cytomegalovirus Infections; Cytosine; Heart Transplantation; | 2016 |
Hyperbaric oxygen therapy in BKV-associated hemorrhagic cystitis refractory to intravenous and intravesical cidofovir: case report and review of literature.
Topics: Administration, Intravesical; Adult; Antineoplastic Agents; Antiviral Agents; BK Virus; Cidofovir; C | 2009 |
Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet.
Topics: Adolescent; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Encephalitis, Viral; | 2009 |
[A 55-year-old woman with thymoma and hypogammaglobulinemia (Good syndrome), ulcerative colitis, and cytomegalovirus infection].
Topics: Agammaglobulinemia; Antiviral Agents; Azathioprine; Cidofovir; Colitis, Ulcerative; Cytomegalovirus | 2009 |
Development of herpes simplex virus stomatitis during receipt of cidofovir therapy.
Topics: Acyclovir; Antiviral Agents; Chemoprevention; Child; Child, Preschool; Cidofovir; Cytomegalovirus In | 2009 |
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
Topics: Administration, Oral; Animals; Antiviral Agents; Cytomegalovirus Infections; Cytosine; Disease Model | 2011 |
Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
Topics: Alkaline Phosphatase; Antiviral Agents; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovirus I | 2012 |
Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2012 |
Antiviral therapy for cytomegalovirus infections in pediatric patients.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Adult; AIDS-Related Opportunis | 2002 |
Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation.
Topics: Acyclovir; Antiviral Agents; Chemoprevention; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections | 2002 |
An animal model of neonatal cytomegalovirus infection.
Topics: Animals; Animals, Newborn; Antiviral Agents; Body Weight; Brain; Cytomegalovirus; Cytomegalovirus In | 2003 |
Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.
Topics: Antigens, Viral; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cidofovir; Cyto | 2004 |
Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy.
Topics: Aged; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA, Viral | 2004 |
Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection.
Topics: Administration, Oral; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infecti | 2004 |
Perianal ulcer in a patient with AIDS.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cidofovir; Cytomegalovirus Infections; Cytom | 2004 |
Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Esters; | 2004 |
Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation.
Topics: Adolescent; Antigens, Viral; Antiviral Agents; Child; Cidofovir; Creatinine; Cytomegalovirus Infecti | 2005 |
Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection.
Topics: Animals; Animals, Newborn; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; | 2006 |
Cidofovir treatment of HIV-associated cytomegalovirus polyradiculopathy.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2006 |
The effect of cidofovir on cytomegalovirus-induced hearing loss in a Guinea pig model.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Disease Models, Animal; | 2006 |
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA Replication; | 2007 |
Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Therapy, Co | 2007 |
Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir.
Topics: Adenine; Antiviral Agents; Cell Line; Cidofovir; Cowpox; Cytomegalovirus Infections; Cytosine; Herpe | 2007 |
Simultaneous development of Fanconi syndrome and acute renal failure associated with cidofovir.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Fanco | 2007 |
A model of human cytomegalovirus infection in severe combined immunodeficient mice.
Topics: Animals; Antiviral Agents; Cell Culture Techniques; Cell Line; Cidofovir; Cytomegalovirus; Cytomegal | 2007 |
Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Cells, Cultured; Cid | 2008 |
Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models.
Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegaloviru | 2008 |
Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2008 |
Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infection | 1995 |
Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; HIV Infections; Humans; Ma | 1995 |
New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine | 1994 |
Comparative effect of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine treatment on cytomegalovirus-induced interstitial pneumonitis in allogeneic bone marrow transplant recipient rats.
Topics: Animals; Antiviral Agents; Bone Marrow Transplantation; Cidofovir; Cytomegalovirus Infections; Cytos | 1993 |
Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine.
Topics: Animals; Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Cidofovir; Cytomegalovirus; | 1993 |
Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice.
Topics: Animals; Animals, Newborn; Antiviral Agents; Brain; Brain Diseases; Cidofovir; Cytomegalovirus; Cyto | 1993 |
Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase.
Topics: Animals; Antiviral Agents; Base Sequence; Cattle; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytom | 1996 |
Treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1996 |
Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infection | 1996 |
Current and experimental therapeutic options for cytomegalovirus disease.
Topics: Administration, Oral; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cyto | 1996 |
Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro.
Topics: Acyclovir; Adenine; Antiviral Agents; Cells, Cultured; Cidofovir; Cytarabine; Cytomegalovirus; Cytom | 1996 |
Combination of antiviral immunotoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infections.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Therapy, Combinatio | 1996 |
Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells.
Topics: Antiviral Agents; Catalysis; Cell Line; Cidofovir; Cytomegalovirus Infections; Cytosine; Humans; Kin | 1996 |
New therapies for cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1997 |
Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA, Viral; Drug | 1997 |
Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis.
Topics: Adult; Antiviral Agents; Cidofovir; Cohort Studies; Cytomegalovirus Infections; Cytosine; Female; Hu | 1997 |
Hypotony and visual loss with intravenous cidofovir treatment of cytomegalovirus retinitis.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Humans; Injections, Intrav | 1997 |
Successful use of cidofovir in treating AIDS-related cytomegalovirus retinitis, encephalitis, and esophagitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infection | 1997 |
Effective treatment of experimental cytomegalovirus-induced encephalo-meningitis in immunocompromised rats with HPMPC.
Topics: Animals; Antiviral Agents; Brain; Cidofovir; Cytomegalovirus Infections; Cytosine; Disease Models, A | 1997 |
Successful treatment of cytomegalovirus encephalitis in an AIDS patient using cidofovir.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1997 |
Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anterior Chamber; Antiviral Agents; Aqueous Humor; Cidofo | 1997 |
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cidofovir; Cytomega | 1997 |
Intravitreal and plasma cidofovir concentrations after intravitreal and intravenous administration in AIDS patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cidofovir; Cohort Studies; Cytomegalovi | 1998 |
Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cidofovir; Cytomegalovirus | 1998 |
Cytomegalovirus iritis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibodies, Viral; Antigens, Viral; Antiviral Agents; | 1998 |
Comment: cidofovir in the treatment of cytomegaloviral disease.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Organophosphonat | 1999 |
Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus In | 1999 |
Uveitis in patients treated with intravenous cidofovir.
Topics: Adult; Anti-HIV Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; HIV Seropositivity; Humans; | 1999 |
The antisense oligonucleotide ISIS 2922 prevents cytomegalovirus-induced upregulation of IL-8 and ICAM-1 in cultured human fibroblasts.
Topics: Antiviral Agents; Cells, Cultured; Chemotaxis, Leukocyte; Cidofovir; Cytomegalovirus Infections; Cyt | 2000 |
Acute murine cytomegalovirus infection: a model for determining antiviral activity against CMV induced hepatitis.
Topics: Alanine Transaminase; Animals; Antiviral Agents; Aspartate Aminotransferases; Body Weight; Cidofovir | 1999 |
Treatment of BK virus-associated hemorrhagic cystitis and simultaneous CMV reactivation with cidofovir.
Topics: Antiviral Agents; BK Virus; Cidofovir; Cystitis; Cytomegalovirus; Cytomegalovirus Infections; Cytosi | 2000 |
CMV complications in common variable immunodeficiency.
Topics: Adult; Antiviral Agents; Azathioprine; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lym | 2000 |
Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals.
Topics: Animals; Antiviral Agents; Cyclophosphamide; Cytomegalovirus Infections; Cytosine; Guinea Pigs; Immu | 2000 |
Ocular side-effects from systemic HPMPC (Cidofovir) for a non-ocular cytomegalovirus infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 2000 |
Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient.
Topics: Antigens, Viral; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; | 2000 |
Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Cidofovir; Cytomegalovirus Infections; | 2001 |
Failure of cidofovir to reduce CMV-antigenemia in a child transplanted from a matched unrelated donor.
Topics: Adenoviridae; Antiviral Agents; Bone Marrow Transplantation; Child; Cidofovir; Cytomegalovirus Infec | 2001 |
Enhancement of transplantation-associated atherosclerosis by CMV, which can be prevented by antiviral therapy in the form of HPMPC.
Topics: Animals; Antiviral Agents; Aorta; Arteriosclerosis; Cidofovir; Cytomegalovirus; Cytomegalovirus Infe | 1994 |
Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation.
Topics: Adult; Antigens, Viral; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cy | 2001 |
Advances, challenges and growing frustration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cachexia; Cidofovir; Cytomegalovirus Infection | 1995 |
Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches.
Topics: Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Child; Cidofovir; Cytomegalovirus; C | 2001 |
Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients.
Topics: Adult; Antiviral Agents; Cell Culture Techniques; Cidofovir; Cytomegalovirus; Cytomegalovirus Infect | 2001 |
Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Disease | 2001 |
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Cidofov | 2001 |
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Topics: Adult; Antiviral Agents; Cidofovir; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; Cytos | 2001 |
Acute renal failure in a lung transplant patient after therapy with cidofovir.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Human | 2001 |
Polymerase chain reaction-based "pre-emptive" therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study.
Topics: Adult; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA, Viral; Hematopoietic S | 2002 |
Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Disease Models, Animal; | 1992 |
Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine.
Topics: Animals; Antifungal Agents; Antineoplastic Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; | 1992 |
Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Ganciclovir; He | 1991 |
Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anti-cytomegalovirus agents.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Ester | 1991 |
Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo.
Topics: Animals; Antiviral Agents; Cell Survival; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytomegalovir | 1991 |
(S)-1-(3-hydroxy-2-(phosphonylmethoxy)propyl)cytosine (HPMPC): a potent antiherpesvirus agent.
Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Cidofovir; Cytomegalovirus Infections; C | 1990 |
Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs.
Topics: Animals; Antiviral Agents; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; | 1990 |
Pyrimidinone (bropirimine) mediated alteration of T lymphocyte subsets during murine cytomegalovirus infection.
Topics: Animals; Cell Division; Concanavalin A; Cytomegalovirus Infections; Cytosine; Female; Immune Toleran | 1987 |